NCT03001076View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

PHASE3CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

January 11, 2018

Study Completion Date

February 12, 2018

Conditions
HypercholesterolemiaAtherosclerosisStatin Adverse Reaction
Interventions
DRUG

Bempedoic acid

bempedoic acid 180 mg tablet

DRUG

Ezetimibe

ezetimibe 10 mg tablet

OTHER

Placebo

matching placebo tablet

Trial Locations (1)

78626

Georgetown

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY